Ontario Bioscience Innovation Organization Canada

The Ontario Bioscience Innovation Organization (OBIO®) is focused on the development of an integrated health innovation economy for Ontario, Canada. The OBIO Capital Access Advisory Program (CAAPTM) is led by OBIO and a North American Steering Committee of life science venture capitalists and serial entrepreneurs to position selected high-potential bioscience companies for financing success. 

Gail Garland
Catherine Love
LinkedIn logo Senior Director 
Dr. Klaus Fiebig
Dr. Klaus Fiebig
LinkedIn logo Senior Director 
BIO

Dr. Fiebig is an entrepreneur and biopharma executive with over 14 years of management experience in academia, industry and not-for-profit (government) organizations.  He is the Senior Director, Strategic Programs at the Ontario Bioscience Innovation Organization (OBIO) and leads OBIO’s Capital Access Advisory Program which has received significant support from FedDev Ontario to strengthen Ontario’s cadre of investable human health technology companies, increasing high value deal flow.  Prior to his role at OBIO, Dr. Fiebig was CSO and VP of Research Programs at Ontario Genomics, a government funding organization, where he oversaw an $800M research program portfolio.  During this time he was responsible for more than 10 funding competitions, a team of research program managers, and Ontario Genomics’ strategic approach to identifying, cultivating, and raising funds for genomics and proteomics projects and platforms in Ontario.  As Senior Director, Structural Biology and Computational Chemistry at Affinium Pharmaceuticals in Toronto he led the structural biology and computational chemistry teams and a 20 FTE strategic alliance with Pfizer on structure-based drug discovery focused on infectious disease.  Prior, Dr. Fiebig founded and managed MRPharm GmbH, a fee-for-service and drug discovery biotech start-up in Frankfurt, Germany and was a lead scientist with Xencor in Los Angeles responsible for improving their automatic computational protein design platform.  Dr. Fiebig has a broad scientific background in the physical and biomedical fields. He trained at Yale University (Post Doctorate), Oxford University (Post Doctorate), University of California at San Francisco (PhD), and the Technical University Munich (undergraduate). He co-authored numerous scientific publications and holds several patents.

The Hospital for Sick Children Canada

The Hospital for Sick Children (SickKids) is Canada’s largest, pediatric research hospital. Our history is one of research innovation. The Research Institute shares SickKids' vision of Healthier Children. A Better World.

SickKids Mission is:
â—¾Advancement of child health through global leadership in innovation, research and discovery.
â—¾Translation of research knowledge to benefit children and families everywhere.

Our research is supported by the generosity of donors who contribute to SickKids Foundation, as well as government agencies, non-profit foundations and companies and organizations that share our goals of improving child health outcomes.

Our research ranges from basic discovery research all the way to clinical care and is supported by state-of-the-art expertise, technologies and facilities. Our research activities are coordinated under seven major research programs, which range from basic science at the sub-molecular level, to organ systems, to population health. The seven programs cover the spectrum of child health from wellness and normal development to causes of diseases, diagnostics, treatments and therapies. Through these programs we cohesively and collaboratively bring together the more than 1,000 funded research projects and these internationally competitive and highly integrated research activities approach child health from all angles and disciplines.

Our scientists collaborate on hospital-wide interdisciplinary projects focusing on molecular therapies, cancer, brain, genetics, organs and chronic diseases and health care policies and practice. To support their research we provide our scientists with access to research expertise, state-of-the art equipment, technologies and services provided by core facilities and other resources.

The SickKids Industry Partnerships and Commercialization (IP&C) office is committed to ensuring that innovations developed at The Hospital for Sick Children have the widest impact possible. IP&C is a collaborative team of professionals with diverse expertise, including business development officers and analysts, communications and marketing professionals, license and royalty managers and intellectual property advisors and technology commercialization specialists.

Arlene Yee
BIO

Dr. Arlene Yee is responsible for technology commercialization and industry engagement activities at the Industry Partnerships and Commercialization Office (IP&C) at The Hospital for Sick Children. She leads a team of professionals at the IP&C where her role includes evaluating and assessing technology disclosures, commercialization of technology opportunities, licensing, spin-off company formation, sponsored research, and industrial liaison. Her vast experience includes commercializing a variety of intellectual property from academic health science institutions, including start-up company formation and licensing.  Arlene has held previous appointments at McMaster University and the University of Guelph.  Arlene has a degree in veterinary medicine and a Masters of Science degree in microbiology from the University of Guelph. She is also a Registered Technology Transfer Professional, a designation that recognizes professionals in the tech transfer and business development areas of the profession. She is an active member of The Licensing Executive Society (LES) and The Association of University Technology Managers (AUTM).

Michael Salter
Chief of Research